Background: It was shown that nonoxidized PTH (n-oxPTH) is bioactive, whereas oxidized PTH at methionine residues results in loss of biological activity.
it was only 453 days in the lowest n-oxPTH tertile. Multivariable-adjusted Cox regression showed that higher age increased odds for death, whereas higher n-oxPTH reduced the odds for death. Another model analyzing a subgroup of patients with intact PTH (iPTH) concentrations at baseline above the upper normal range of the iPTH assay (70 ng/L) revealed that mortality in this subgroup was associated with oxidized PTH but not with n-oxPTH levels.
Conclusions:
The predictive power of n-oxPTH and iPTH on the mortality of hemodialysis patients differs substantially. Measurements of n-oxPTH may reflect the hormone status more precisely. The iPTH-associated mortality is most likely describing oxidative stress-related mortality. (J Clin Endocrinol Metab 98: 0000 -0000, 2013) E xcess mortality in patients with chronic kidney disease stage 5 compared with the general population is still an important unsolved problem. The annual mortality of patients with chronic kidney disease stage 5 is about 10%-20%. Too low or too high levels of PTH are considered to be one of the most important factors contributing to the excess mortality in patients requiring hemodialysis. A recent huge study demonstrated a U-shaped association between PTH and mortality. Low as well as high PTH levels measured by current PTH assays are associated with substantially increased all-cause mortality in patients on hemodialysis (1) . PTH levels are associated with cardiovascular diseases and bone diseases (2) . Because PTH is considered to play a pivotal role in cardiovascular disease progression and mortality of patients with chronic renal failure, there are international guidelines recommending target levels (2, 3) . The Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines recommend that PTH concentrations of patients with chronic kidney disease (CKD) should be measured regularly and maintained within target ranges that are defined according to the stage of CKD (eg, 150 -300 ng/L in patients with CKD stage 5). As reviewed earlier by Souberbielle et al (3) , the quality of the PTH assay is of paramount importance because it contributes to the therapeutic decision.
PTH is secreted by the chief cells of the parathyroid glands as a polypeptide containing 84 amino acids. PTH increases blood calcium by activation of PTH 1 receptor, showing high levels in the bone and kidney. The second PTH receptor (PTH 2 receptor) is expressed mainly in the central nervous system, pancreas, testis, and placenta. The half-life of PTH is approximately 4 minutes. Oxidation of PTH at methionine residues 8 and/or 18 results in the loss of its biological activity (4 -6) . Classical third-generation intact PTH (iPTH) sandwich assays do not differentiate between biologically active nonoxidized PTH (n-oxPTH) and biologically nonactive oxidized PTH (oxPTH). Using very sensitive mass spectroscopy approaches, we recently demonstrated that oxidation of human PTH(1-84) resulted in the formation of a variety of products corresponding to the different oxidized methionine resides at position 8 and/or 18 within the PTH (7) . We demonstrated that a column with a monoclonal antibody raised against the oxidized PTH can remove all oxidized forms of PTH(1-84) from plasma samples. Another recent study using this new method to measure nonoxidized PTH in approximately 1500 patients with chronic renal failure showed that a huge proportion of circulating PTH measured by current state-of-the-art assay systems is oxidized and thus not biologically active. The relationship between the oxPTH and n-oxPTH of individual patients varied substantially. Nonoxidized PTH concentrations are 1.5-to 2.25-fold higher in patients with renal failure as compared with health controls. Additionally, it was shown that neither the oxPTH to n-oxPTH ratio nor the n-ox-PTH concentration changed over time after taking blood samples (8) .
The objective of the present study was to evaluate the association of nonoxidized, biologically active PTH with all-cause mortality in hemodialysis patients.
Materials and Methods

Patients
For determining associations of n-oxPTH and iPTH levels with mortality in hemodialysis patients, we performed a prospective cohort study in prevalent 340 hemodialysis patients, who were followed up for 5 years. Our eligibility criteria were broad and included all adult patients on hemodialysis treatment due to end-stage CKD stage 5 and the presence of informed consent. Informed consent from each patient and ethical approval by the local ethics committee were obtained. Data on dialysis vintage at inclusion and duration of hemodialysis treatment per session were obtained. All of the patients were routinely dialyzed for 4 -5 hours three times weekly using biocompatible membranes with no dialyzer reuse. Blood flow rates were 250 -300 mL/min, dialysate flow rates were 500 mL/min, and dialysate conductivity was 135 milliseconds. Blood pressure was measured before dialysis. Predialysis blood samples were taken at study entry. Blood for PTH measurements (see below) was collected immediately before the start of the hemodialysis session.
One hundred seventy patients (50%) died during the follow-up time of 5 years. The causes of death were classified as cardiovascular including sudden death, infection, or cancer.
Clinical and laboratory data included age, gender, medications (use of angiotensin converting enzyme inhibitors, ␤-blockers, calcium channel blockers, and erythropoietin), body mass index (calculated as body weight divided by height squared), systolic and diastolic blood pressure (BP), serum albumin, serum cholesterol, serum triglycerides, serum urea, serum creatinine, serum calcium, serum potassium, and serum phosphate.
PTH measurements
PTH was measured by means of the third-generation iPTH electrochemiluminescence immunoassay system (iPTH electrochemiluminescence immunoassay (ECLIA; Roche iPTH; Roche Diagnostics) either directly (iPTH) and after prior removal of oxPTH molecules from the samples using specific monoclonal antibodies raised against the oxidized human PTH (n-oxPTH).
Removal of oxPTH was performed using the antihuman oxidized PTH monoclonal antibody (Immundiagnostik AG). The antihuman oxPTH monoclonal antibody was immobilized on CNBr-activated Sepharose 4B (GE Healthcare Bio-Sciences). A 100-L aliquot of the slurry was filled in a column (MobiSpinColumn; MoBiTec) and equilibrated with PBS buffer (pH 7.4). Then 500 L of plasma samples was applied on the columns, which were incubated mixing end over end for 2 hours at room temperature, and washed with 250 L of 0.1 M ammonium acetate buffer (pH 7.0), followed by a wash with 250 L of 0.1 M ammonium acetate buffer (pH 7.0), containing 20% acetonitrile and then eluted two times with 200 L of elution buffer (0.05 M formic acid, pH 3.5). Flow-through was collected separately and lyophilized. Then the samples were reconstituted in 500 L of PBS buffer (pH 7.4) and analyzed for iPTH. An iPTH ECLIA (Roche iPTH; Roche Diagnostics) uses a biotinylated monoclonal antibody, which reacts with amino acids 26 -32, and a capture ruthenium-complexed monoclonal antibody, which reacts with amino acids 55-64. The determinations were performed on a Roche Modular E 170. As previously described, the intraassay coefficient of variation was 4.1% and the interassay coefficient of variation was 5.8% at concentrations of 35.0 and 180.0 ng/L, respectively, for the whole procedure (removal of oxPTH and measuring PTH).
The Osteoprotegerin ELISA K 1011 (Immundiagnostik AG) was used to measure osteoprotegerin. The 25-hydroxyvitamin D Xpress ELISA K 2107 (Immundiagnostik AG) was used to measure 25-hydroxyvitamin D.
Statistical analysis
Continuous variables were expressed as the median with interquartile range (IQR) and compared with a nonparametric Mann-Whitney U test or a nonparametric Kruskal-Wallis test and Dunn's multiple comparison post hoc test, where appropriate. Associations between variables were tested using nonparametric Spearman correlation. Time-to-event analyses were performed using the Kaplan-Meier method. Comparison of survival curves were performed using the log-rank (Mantel-Cox) test. Categorical variables were expressed as proportions and compared with the 2 test. Multivariable-adjusted survival analyses were performed using the proportional hazards regression model. Multivariable models were constructed with backward variable selection, using P Ͻ .05 for variable retention. Forty-five patients (13%) underwent kidney transplantation during the follow-up. These patients were censored on the day of transplantation. All hypothesis tests were two sided, with statistical significance defined as having a P Ͻ .05. Statistical analyses were conducted using GraphPad Prism 5.0 (GraphPad Software) or SPSS for Windows (version 15; SPSS).
Results
A total of 340 hemodialysis patients (224 men and 116 women) with a median age of 66 years (IQR 56 -75 y), a median time since the initiation of dialysis (dialysis vintage) of 266 days (IQR 31-1209 d), and a median dialysis dose (kt/V) of 1.2 (IQR 1.1-1.3) entered into the study (kt/V is a number used to quantify hemodialysis and peritoneal dialysis treatment adequacy/quality, where k is the dialyzer clearance of urea, t is the dialysis time, and V is the volume of distribution of urea, approximately equal to the patient's total body water). The cause of chronic kidney disease was nephrosclerosis in 113 cases (33%), diabetic nephropathy in 107 cases (31%), chronic glomerular nephritis in 29 cases (9%), polycystic kidney disease in nine cases (3%), and other or unknown in 82 cases (24%). The mean iPTH of the entire cohort at study entry was 105.22 Ϯ 160.43 g/L; mean oxPTH of the entire study cohort at study entry was 93.83 Ϯ 142.02 g/L; mean n-oxPTH of the entire study cohort at study entry was 11.77 Ϯ 20.88 g/L. Figure 1 shows the distribution of n-oxPTH concentrations in 340 hemodialysis patients. The median n-ox-PTH concentration was 5.9 ng/L (IQR 2.4 -14.0 ng/L). The n-oxPTH concentrations were not different in men and women (5.9 ng/L, IQR 2.4 -14.2 ng/L, n ϭ 224, vs 5.5 ng/L, IQR 2.4 -14.0 ng/L, n ϭ 116; P ϭ .915). Table 1 summarizes the distribution of cases and several laboratory variables stratified by tertiles of n-oxPTH. Tertile limits were n-oxPTH concentrations of 3.3 and 10.3 ng/L, respectively. Hemodialysis patients of the upper n-oxPTH tertile had higher weight, body mass index, and higher urea, a proxy for dietary protein intake, higher creatinine, a proxy for muscle mass, and typical signs of impaired mineral metabolism, ie, lower serum calcium and higher serum phosphorous concentrations.
Furthermore, serum phosphorus concentrations were directly (Spearman r ϭ 0.245; P Ͻ .001) and serum calcium concentrations were inversely (Spearman r ϭ Ϫ0.160; P ϭ .004) correlated with n-oxPTH concentrations. The use of vitamin D analogs did not affect n-oxPTH levels. In 235 patients without vitamin D analogs, the median n-oxPTH concentration was 6.2 ng/L (IQR 2.5-14.6 ng/L), whereas in 105 patients with vitamin D analogs, the median n-oxPTH concentration was 5.4 ng/L (IQR 2.3-13.4 ng/L; P ϭ .36). On the other hand, age (Spearman r ϭ Ϫ0.099) and dialysis vintage (Spearman r ϭ 0.098) were not significantly correlated with noxPTH. Neither CrP concentrations nor baseline leukocyte count was correlated with oxPTH at baseline (data not shown).
A correlation matrix showing Spearman's correlation coefficients for the correlating of iPTH to either n-oxPTH or oxPTH revealed that the correlation of iPTH to oxPTH was very good, close to one, in the entire study population and also the subgroup of patients with elevated iPTH (iPTH above the upper normal range of iPTH; see also Table 2 ). However, the correlation was much weaker when analyzing the relationship between iPTH and n-ox-PTH. In particular, in patients with elevated iPTH, the correlation was weak ( Table 2 ). The correlation for the entire study group is illustrated in Figure 2 .
One hundred seventy patients (50%) died during the follow-up time of 5 years. Death occurred at a median of 217 days (IQR 67-564 d) after study entry. The causes of death were cardiovascular diseases in 102 patients (60%), infections in 39 patients (23%), cancer in 19 patients (11%), and other/unknown reasons in 10 (6%). Median n-oxPTH levels were higher in survivors (7.2 ng/L; IQR 3.1-16.5 ng/L) compared with deceased patients (5.0 ng/L; IQR 1.9 -11.1 ng/L; P ϭ .002 by Mann-Whitney U test). Survival analysis showed an increased survival in the upper n-oxPTH tertile compared with the lower n-oxPTH tertile ( 2 , 14.30; P ϭ .0008 by log rank test). Median survival was 1702 days in the upper n-oxPTH tertile, whereas it was only 453 days in the lower n-oxPTH tertile ( Figure 3) . When analyzing the cohort by tertiles of noxPTH, BP was not significantly different between the groups (systolic BP, P ϭ .326; diastolic BP, P ϭ .185). Diabetes was not significantly different between the groups (P ϭ .076). Serum creatinine and serum phosphorus were significantly different between the groups (each P ϭ .001).
Next, we performed multivariable-adjusted survival analyses using the proportional hazards regression model with backward variable selection, using P Ͻ .05 for variable retention. Variables tested were plasma n-oxPTH, iPTH category, dialysis dose, dialysis vintage, age, hemoglobin, hypertension, diabetes, serum creatinine, and serum phosphorus. The data are given in Table 3 . The noxPTH, age, and hemoglobin concentrations and serum We analyzed the correlation between iPTH to either n-oxPTH or oxPTH in the whole study population and also in the patients with iPTH greater than 70 ng/L (P Ͻ .01 in all cases).
Figure 2.
Correlation of iPTH to n-oxPTH in the entire study population. Spearman's correlation coefficient was R ϭ 0.888 (P Ͻ .01). When going to patents with higher iPTH concentrations, the correlation becomes weaker (see also Table 2 ).
creatinine at baseline predicted death in hemodialysis patients, whereas iPTH category, dialysis dose, dialysis vintage, hypertension, diabetes, and serum phosphorus were not predictive. Furthermore, a model analyzing only patients with iPTH above the upper normal range in healthy controls (70 ng/L) revealed that mortality in this subgroup depended on protein oxidation of iPTH but not on biologically active n-oxPTH. In other words, n-oxPTH had no impact on mortality in patients with iPTH levels above the upper normal range, whereas in these patients iPTH was associated with all-cause mortality (Figure 4) .
Using another model, we a priori stratified iPTH levels into five categories according to international guidelines, representing very low (Ͻ20 ng/L), low (20 -65 ng/L), medium (65-150 ng/L), target (150 -300 ng/L), and high (Ͼ300 ng/L). Survival analysis showed a J-shaped pattern, ie, patients with target iPTH levels had longer median survival compared with the other categories ( 2 , 16.35; P ϭ .0026 by log rank test). This U-shaped pattern between iPTH levels and outcome is characteristic for hemodialysis patients, thereby confirming that our data were obtained from a typical hemodialysis cohort ( Figure 5 ). As shown in Figure 6 , median n-oxPTH was higher in 170 patients who survived the first year (including censored subjects) compared with 108 patients who died during the first year (7.2 ng/L, IQR 3.1-16.5 ng/L, vs 4.4 ng/L, IQR 2.0 -9.3 ng/L; P ϭ .002). Furthermore, median iPTH was higher in 170 patients who survived the first year (including censored subjects) compared with 108 patients who . Kaplan-Meier survival curves for all-cause mortality in hemodialysis patients with iPTH plasma concentrations higher than the upper normal range of this assay in healthy controls (70 ng/L). One hundred thirty-eight patients had an iPTH above the upper normal range and thus entered this subgroup analysis of patients with elevated iPTH. These 138 patients with high iPTH were analyzed for survival in two ways. A, The 138 patients were stratified according to the median of n-oxPTH concentrations in two equal groups with 69 patients. Nonoxidized PTH in this subgroup of patients with iPTH concentrations above the upper range of the iPTH assay had no impact on mortality (log rank test, 2 , 0.046; P ϭ .80). B, The 138 patients were stratified according to the median of iPTH in this subgroup into two equal groups with 69 patients each. The iPTH concentrations in this subgroup showed a clear effect on all-cause mortality (log rank test, 2 , 3.852; P ϭ .049). 
Discussion
The present study distinguishes the effects of n-oxPTH and iPTH on the survival of hemodialysis patients. The n-oxPTH measurements were performed using a recently described iPTH ECLIA system after prior removal of ox-PTH molecules from the samples using specific monoclonal antibodies raised against oxidized human PTH (8).
The present study indicates that hemodialysis patients in the upper n-oxPTH tertile showed an increased survival compared with the lower n-oxPTH tertile. After multivariable adjustment, higher n-oxPTH tertile reduced, whereas higher age increased, the odds for death in hemodialysis patients. The validity of the present study is strengthened by the fact that stratification of iPTH data from our cohort into five categories according to the American K/DOQI guidelines revealed that hemodialysis patients with target iPTH levels according had longer median survival compared with the other categories. This U-shaped survival pattern confirms results derived from the iPTH data from a large mortality meta-analysis (1). Current PTH assays do not distinguish between oxidized and nonoxidized PTH forms, although it is well known that oxidation of PTH at methionine residues 8 and/or 18 results in loss of its biological activity (4 -8) . Our analysis in a subgroup of hemodialysis patients having iPTH above the upper normal range in healthy controls (70 ng/L) clearly separated the true effects of the bioactive nonoxidized hormone from the harmful effects of oxidative stress on mortality. We observed that increased mortality in this subgroup depended on protein oxidation of PTH but not on biologically active n-oxPTH.
It would be very interesting to extend this analysis to dialysis patients with very high iPTH concentrations, which means patients who are considered to have secondary hyperparathyroidism according to classical diagnostic standards. Unfortunately, the number of patients with such high iPTH concentrations in our study cohort was too low to allow clear statements. Analyses from cohorts of dialysis patients with secondary hyperparathyroidisms as investigated in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events study cohort (9) may help to address this important clinical question.
Our findings that n-ox PTH levels are generally low relative to iPTH fit very well with earlier studies in patients with renal failure using bioassays for PTH reported in the early 1980s by Goltzman et al (23) . The investigators determined PTH levels by a renal cytochemical bioassay and by midregion and carboxyl-terminal RIAs. Baseline PTH levels were substantially lower in each patient when assessed by bioassay as compared with determination by RIA. These results emphasize the discordance between the levels of bioactive and immunoreactive hormone when kidney function is impaired (23) . Our findings might thus explain the discordance observed by Goltzman et al (23) more than 30 years ago because in uremic patients in general, a huge fraction of total circulating PTH is oxidized and hence biologically inactive and not detectable by a bioassay.
Current guidelines recommend to measure iPTH levels routinely and to obtain target iPTH levels (ie, from 150 to 300 ng/L) because several studies, including the present investigation, observed worse outcomes with iPTH levels above 300 ng/L. In contrast, our study investigating noxPTH showed that hemodialysis patients in the upper tertile, ie, n-oxPTH levels above 10.3 ng/L, had an increased survival. At first glance these findings may be surprising, but several factors may serve as an explanation for this. First, as already mentioned, we had only a very few patients with iPTH concentrations above 300 ng/L in our dialysis cohort. Therefore, we could not make statements for this subcohort. Second, it is well known that the halflife of oxidized iPTH far exceeds the half-life of nonoxidized iPTH (10, 11) . Plasma iPTH is mainly cleared by the liver and the kidney. Hruska et al (11) showed that the metabolic clearance rate of oxidized iPTH was largely reduced compared with nonoxidized iPTH. They reported that the metabolic clearance rate of nonoxidized iPTH was 21.6 mL/min per kilogram of body weight, whereas the metabolic clearance rate of oxidized iPTH was only 8.8 mL/min per kilogram of body weight (11) . Therefore, high iPTH levels may merely represent PTH exposed to increased oxidative stress. The negative impact of increased oxidative stress on the outcome of hemodialysis patients has already been established by several groups (12) (13) (14) (15) .
There are data indicating that the association between PTH concentrations, measured by a second-generation iPTH assay, and mortality in dialysis patients is modified by wasting (16, 17) . On the other hand, wasting is associated with inflammation and oxidative stress (18) . Thus, the modulation of the impact of PTH on mortality by wasting might be related to oxPTH rather than to n-oxPTH. However, this possibility needs to be proven in future studies.
Removal of the parathyroid glands in animal models of uremia as well as in patients suffering from hyperparathyroidism clearly proves that high concentrations of nonoxidized PTH contributes to vascular calcification and hence cardiovascular morbidity and mortality in uremia (19 -22) . At the same time, it is also true that oxidative stress is related to cardiovascular mortality in end-stage renal disease patients as well (12) (13) (14) (15) . Our data thus may indicate that the U-shaped survival curve for iPTH (1) most likely represents an overlay of two curves describing two different biological processes: first, mortality related to biologically active, nonoxidized PTH, and second, mortality related to oxidative stress reflected by oxidized PTH. Current iPTH assays cannot differentiate these PTH forms because they are measuring both oxidized and nonoxidized PTH. We are aware that the final proof of this hypothesis needs more and larger studies. Moreover, none of the patients was operated because of tertiary hyperparathyroidism or had calciphylaxia. In our cohort we observed that iPTH in patients on dialysis with high iPTH levels rather reflected oxidative stress than PTH bioactivity. The diagnostic criteria for tertiary hyperparathyroidism using the n-oxPTH measurements need to be reevaluated in a larger sample with established calciphylaxia.
Why and how PTH is oxidized in vivo is unknown so far. It is only clear that PTH oxidation is an in vivo phenomenon and does not occur to a relevant amount ex vivo (8) . Our previous work (8) indicated that oxidative stress plays a major role because the degree of PTH oxidation is much less pronounced in patients without oxidative stress. A very interesting recent animal study (24) demonstrated that oxidized lipids attenuate osteogenesis and that PTH bone anabolism is blunted in hyperlipidemic mice and that D-4F, an apolipoprotein A-I mimetic peptide, attenuated serum lipid oxidation products and tissue lipid deposition induced by a high-fat diet. D-4F treatment attenuated the adverse effects of dietary hyperlipidemia on PTH anabolism by restoring microcomputed tomographic parameters of bone quality: cortical mineral content, area, and thickness (24) . D-4F significantly reduced serum markers of bone resorption but not bone formation. PTH and D-4F, together but not separately, also promoted bone anabolism (24) . Based on this important work, we speculate that under conditions of lipid oxidation, protein oxidations also occur and treatment of lipid oxidation using D-4F may also affect PTH oxidation in vivo. However, this needs to be proven in further studies.
The present study may indicate that guidelines for target PTH levels in dialysis patients should consider n-ox-PTH measurements in the future because only n-ox PTH is biologically active [see literature review in the discussion of reference (8)].
In conclusion, the predictive power of n-oxPTH and iPTH for all-cause mortality differs substantially. Because the classical iPTH assay detects mainly oxidized, biologically inactive PTH, clinical decisions based on iPTH measurements may be misleading in patients with end-stage renal disease. Our findings may underscore the need for implementation of novel PTH guidelines and updated assay procedures to improve therapeutic strategies. have nothing to disclose. All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest.
